Invivyd (IVVD) reported third-quarter 2026 net product revenue of $15.4 million, up 18% from $13.1 million a year earlier. The company posted a net loss of $33.5 million, or $0.10 per basic and diluted share, for the quarter ended September 30.
Cash and cash equivalents totaled $126.4 million at quarter-end. Invivyd said interim data from its DECLARATION Phase 3 trial of VYD2311 are expected imminently under its planned accelerated-approval regulatory approach.
- GAAP revenue was $15.449 million, compared with $13.129 million in the prior-year quarter.
- Research and development expense was $18.736 million, versus $8.046 million a year earlier.
- Selling, general and administrative expense was $30.349 million, compared with $15.018 million.
- Marc W. Elia, the company’s chairman, was appointed chief executive officer in September 2026.
- Invivyd announced positive topline results from the LIBERTY Phase 3 trial and initiated the FLINTLOCK Phase 2 trial of VYD2311.
$IVVD Insider Trading Activity
$IVVD insiders have traded $IVVD stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $IVVD stock by insiders over the last 6 months:
- JILL ANDERSEN (Chief Legal Officer, Secretary) has made 0 purchases and 2 sales selling 67,962 shares for an estimated $52,780.
- WILLIAM E. DUKE (Chief Financial Officer) has made 0 purchases and 2 sales selling 40,780 shares for an estimated $31,670.
- JULIE GREEN (Chief Human Resources Officer) has made 0 purchases and 2 sales selling 40,780 shares for an estimated $31,670.
- TIMOTHY EDWARD LEE (Chief Commercial Officer) has made 0 purchases and 2 sales selling 40,780 shares for an estimated $31,670.
- ROBERT D. III ALLEN (Chief Scientific Officer) has made 0 purchases and 2 sales selling 37,722 shares for an estimated $29,295.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$IVVD Hedge Fund Activity
We have seen 81 institutional investors add shares of $IVVD stock to their portfolio, and 79 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- EVENTIDE ASSET MANAGEMENT, LLC removed 9,071,995 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $7,914,408
- BVF INC/IL added 8,640,000 shares (+44.3%) to their portfolio in Q2 2026, for an estimated $7,537,536
- POINT72 ASSET MANAGEMENT, L.P. added 7,498,130 shares (+17068.0%) to their portfolio in Q2 2026, for an estimated $6,541,368
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 3,630,351 shares (-43.0%) from their portfolio in Q2 2026, for an estimated $3,167,118
- BALYASNY ASSET MANAGEMENT L.P. removed 3,515,644 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $3,067,047
- SATURN V CAPITAL MANAGEMENT LP removed 2,556,796 shares (-23.4%) from their portfolio in Q2 2026, for an estimated $2,230,548
- PERCEPTIVE ADVISORS LLC removed 2,368,667 shares (-11.4%) from their portfolio in Q2 2026, for an estimated $2,066,425
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.